The UK and US have reached a major trade agreement that will guarantee no import taxes on UK drug shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the NHS. This pledge guarantees that tariffs on these key exports will be held at nothing for a period of 36 months.
This development comes after previous statements to hike import taxes on patented drug imports, with potential rates discussed reaching double the cost.
"This deal with the Britain bolsters the global environment for new treatments and establishes much-needed fairness to transatlantic medicine commerce," a statement noted.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's biggest goods shipped to the United States, which is easily the biggest destination for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to the third quarter, the UK sold drugs valued at £11.1bn to the US. This value accounted for a significant portion of all goods exports in that span.
"This guarantee safeguards work, increases funding and facilitates the UK to become a international leader for life sciences," a government official commented.
Detailed NHS Changes
The agreement entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to raise total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates were more than twenty percent.
Industry Background
The pact follows a protracted row between the sector and the ministers over spending levels and NHS adoption.
The disagreement were intensified by assertions that American consumers were charged significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while major expansions have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
